View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 10, 2016updated 13 Jul 2022 10:15am

Seres starts PhaseIb trial of SER-262 to treat clostridium difficile infection

US-based microbiome therapeutics platform company Seres Therapeutics has commenced the Phase Ib clinical trial of SER-262 to treat primary Clostridium difficile infection (CDI).

Seres

US-based microbiome therapeutics platform company Seres Therapeutics has commenced the Phase Ib clinical trial of SER-262 to treat primary Clostridium difficile infection (CDI).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

SER-262 is an Ecobiotic rationally-designed, fermented microbiome therapeutic, which is administered orally.

It is sythentically derived and requires no human donor material.

The capsule comprises a combination of 12 bacterial strains in spore form selected on the basis of criterion, which are human microbiome analysis, efficacy in animal models of CDI, and bacterial strain level characterisation.

Around 60 patients with CDI will be involved in the randomised, placebo-controlled, dose escalation Phase Ib trial, to be conducted over a period of 24 weeks.

The trial is primarily focused on comparing the CDI recurrence rate between the SER-262 and placebo groups after dosing them for eight weeks.

"The SER-262 programme has demonstrated our ability to rapidly develop a new class of synthetic microbiome therapeutics comprised of rationally designed bacterial compositions."

Seres president CEO and chairman Roger Pomerantz said: "The SER-262 programme has demonstrated our ability to rapidly develop a new class of synthetic microbiome therapeutics comprised of rationally designed bacterial compositions.

"We intend to continue to utilise our platform technology and unique knowledge of bioinformatics, microbiology, manufacturing and regulatory requirements to develop additional rationally designed microbiome therapeutics for serious diseases in each of our three therapeutic franchises: infectious disease, immunology and metabolic disease."

The company is currently also undertaking SER-109 Phase II trial to treat multiply recurrent CDI.

The initial study results from the SER-109 Phase II study are expected this year.


Image: Clostridium difficile occurrence on a blood agar plate. Photo: courtesy of CDC/Dr. Holdeman via Wikipedia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena